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Abstract The diuretic drug amiloride is a specific inhibitor of 
sodium transporting proteins in several cell types. Attempts to 
inhibit this activity in membrane vesicles derived from various 
bacteria, did not yield clear results. Therefore, we tested the 
effect of amiloride and its derivatives on the purified Na÷/H + 
antiporters of E. coli reconstituted in functional form in prote- 
oliposomes. Whereas NhaA is not inhibited by amiloride, both 
amiloride and harmaline are potent inhibitors of NhaB with K0.s 
of 6 and 15 pM, respectively. The pattern of inhibition by amilo- 
ride derivatives is different from that reported for mammalian 
antiporters but similar to that reported for the Na÷/H + antiporter 
of D. salina [Katz, A., Kleyman, T.R. and Pick, U. (1994) 
Biochemistry 33, 2389-2393]. Clonidine is a poor inhibitor 
(K0.s = 200 pM) while cimetidine had no effect on the antiporter 
up to concentration of 1 mM. These new potent inhibitors provide 
us with important tools for the study of the mechanism of action 
of NhaB. 
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1. Introduction 
Sodium extrusion and maintenance of a sodium concentra- 
tion gradient, directed inward, is a feature common to all living 
cells. This gradient is generated by primary sodium pumps or 
by secondary transporters, namely Na+/H + antiporters. In 
E. coli there are two specific Na+/H + antiporters namely NhaA 
and NhaB [1], The structural genes coding for the two systems 
were cloned and sequenced [2,3]. NhaA is essential for growth 
at high salt concentrations, a necessity which is increased with 
the pH [4]. NhaB is vital for growth on sodium/cotransported 
substrates such as glutamate and proline on low salt media at 
low pH [5]. A mutant in which both genes were deleted is 
extremely sensitive to sodium and lithium but is able to grow 
throughout the pH range of the wild type provided that the salt 
content is kept low [5]. 
Both proteins were studied in a purified and reconstituted 
system in proteoliposomes [6,7]. NhaA activity is extremely pH 
dependent, changing its rate by three orders of magnitude when 
the pH is changed from 6.5 to 8.5. The pH affects also the 
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apparent Km of NhaB to Na ÷ which increases by 10-fold when 
the pH is shifted from 8.5 to 7.2. Both NhaA and NhaB are 
electrogenic with stoichiometries of 2H+/1Na ÷and 3H+/2Na +, 
respectively [6,7]. 
To study the contribution of each antiporter at different 
growth conditions and to understand their mechanism of ac- 
tion, it is important to characterize other ligands and inhibitors. 
Because of the presence of two antiporters, a reconstituted 
system is most suitable to test properties which could not easily 
or unequivocally be tested in intact cells or isolated membrane 
vesicles. Sensitivity of the antiporter to amiloride and other 
drugs is an example. 
The diuretic drug amiloride is a specific inhibitor of sodium 
transporting proteins in several cell types. It is a competitive 
inhibitor of plasma membrane Na+/H + antiporter in animal 
cells as well as epithelial Na ÷ channels [8]. In algae and plants 
it has been shown to inhibit onoplast [9] and plasma membrane 
[10] Na+/H + antiport activity. The Na+/H ÷ antiporter of 
methanogenic bacteria was also found to be inhibited by both 
amiloride and harmaline [11]. 
There is some controversy whether amiloride inhibits also the 
Na+/H + antiport activity of E. coli. It was reported that the 
Na+/H ÷ exchange activity is competitively inhibited by amilo- 
ride (K~ = 40 pM) when measured with inverted membrane 
vesicles by monitoring quenching of acridine orange [12]. How- 
ever, attempts to inhibit this activity with amiloride in mem- 
brane vesicles derived from wild type (nhaA÷nhaB +)strains did 
not yield clear results [1,13]. It was suggested that amiloride and 
some of its derivatives may inhibit due to their uncoupling 
activity and therefore it was hard to differentiate between spe- 
cific and non-specific effects of amiloride on ApH driven Na ÷ 
transport [13,14]. 
Purified NhaA reconstituted into liposomes, was found resis- 
tant to amiloride; there was no significant inhibition of down- 
hill sodium efflux catalyzed by purified NhaA [6]. In this study, 
using the purified and reconstituted NhaB, we found that NhaB 
is specifically and competitively inhibited by amiloride and har- 
maline at concentrations of 10 20/tM. Analysis of the potency 
of amiloride derivatives reveals anew pattern distinct from that 
displayed by mammalian antiporters. 
2. Materials and methods 
2.1. Bacterial strains, plasmids and culture media 
The bacterial strain used is NM8! [4], an E. coli K12 derivative which 
is melBLid AIaeZY AnhaA1 kan R thrl. pGP1-3 [7] is a derivative of 
pGP1-2 [15] and contains the T7 polymerase gene and tet r instead of 
kanr. Cells were grown in enriched LB media containing 2% bacto 
tryptone, 1% yeast extract 0.5% KCI, 0.2% glycerol and 50 mM KP~, 
pH 7.2. Medium used for labeling of NhaB with [35S]methionine was 
minimal Medium A without sodium citrate supplemented with thia- 
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mine (2.5 pg/ml), threonine (50 pg/ml) and glycerol (0.5%). Ampicillin 
and tetracycline were added to 100 and 10 pg/ml, respectively. 
2.5. Sodium efflux 
Proteoliposomes were made by dilution into a buffer containing 100 
mM potassium acetate, 1 mM DTT, buffered with 10 mM Tris or 
phosphate, pH 7 or 7.5, and sodium at the concentration mentioned in
the figure legend. After thawing, 22NaC1 was added to the prote- 
oliposomes to 15 pCi/ml and the mixture was sonicated to clarity. 
Dilution of 4 pl proteoliposomes was made to 500 ktl of the above buffer 
but without sodium. The assay was terminated with ice-cold dilution 
buffer (2 ml), filtered and washed. Infinite time equilibrium values 
obtained after incubation of 1.5-2 h were subtracted from all experi- 
mental points. 
2.2. Overproduction, membrane preparation and protein purification 
All overproduction a d preparation steps were as described in Pinner 
et al, [7]. NM8 l/pGP1-3/pEL76 (NhaB overexpressing strain) cells were 
grown in rich LB media and induced by a heat shock at OD60 o= 1.5. 
Membrane vesicles were prepared by sonication and washed with 5 M 
urea. The membrane vesicles were mixed with membranes from the 
same strain (grown in minimal medium) in which NhaB was specifically 
labeled with [35S]methionine [7]. Membrane vesicles (1 ml) were solubil- 
ized by addition of 2 ml of a mixture containing 1.5% dodecyl maltoside 
(DM), 7.5 mg/ml E. coli phospholipids, 150 mM MOPS, pH 7, 30% 
glycerol and 3 mM DTT. The extract was diluted and applied on 
hydroxylapatite (HTP) column. Elution was carried out by washing the 
column with a linear gradient of KP, (pH 7) from 0.4 to 1 M. Fractions 
with the highest amount of radioactivity were pooled and frozen after 
the glycerol concentration was raised to 20%. At this point NhaB is 
highly enriched although not homogeneous [7]. 
2.3. Reconstitution 
As described by Taglicht et al. [6] and Pinner et al. [7]. Protein after 
HTP (400 pl) was added to a sonicated mixture (300 pl) containing 8 mg 
of PL in 1.2% OG, 100 mM MOPS, pH 7. The mixture was diluted 
36-fold into the appropriate buffer, depending on the assay used (this 
buffer determines the composition of the internal volume). After 20 min 
at room temperature, proteoliposomes were pelleted by centrifugation 
at 257,000 x g for 1 h, resuspended to 100/11 with the dilution buffer, 
frozen in liquid air and stored at -70°C. When assayed, an aliquot was 
thawed at room temperature and sonicated briefly until clear. 
2.4. ApH driven sodium uptake 
4 pl proteoliposomes, loaded with 150 mM ammonium chloride, 
1 mM DTT and 15 mM Tris, pH 7, were diluted into 500/~1 of 150 mM 
choline-Cl, 15 mM Tris, pH 8.5, and 0.5 1 /ICi/ml 22NaC1 with the 
appropriate drug. The reaction was done at room temperature and 
stopped by addition of 2 ml of ice-cold dilution buffer, filtered on 0.2 
pm Schleicher and Schuell filters and washed with additional 2 ml 
buffer. Radioactivity on the filter was measured in a ),-counter. Zero 
times were made with the addition of 1 mM amiloride and subtracted 
from all experimental points. 
2,6. Protein determination 
Protein was determined by the methods of Bradford [16] and Peter- 
son [17]. 
2.7. Materials 
Hydroxylapatite and octyl glucoside were from Calbiochem; dodecyl 
maltoside, amiloride, HMA and harmaline were from Sigma; EIPA was 
a gift from Dr. Steven Karlish (Weizmann Institute of Science, Re- 
hovot); MIBA a gift from Dr. Marc Solioz (University of Bern); and 
DMA and benzamyl amiloride from Merck and Co. 22NaC1 was from 
Dupont-New England Nuclear and [35S]methionine was from Amer- 
sham Co, 
3. Results 
A 
Since it has been reported that amiloride has uncoupling 
activity [13,14], the effect of this drug was first tested on ApH 
independent reactions, namely Na + efflux and Z2Na+:Na + ex- 
change. The preparation we used for all the experiments de- 
scribed in this communicat ion is purified NhaB reconstituted 
into proteoliposomes [7]. When NhaB proteoliposomes were 
loaded with K-acetate and 22Na and diluted to a buffer of the 
same composit ion but free of sodium, a rapid 22Na+ efflux was 
measured (Fig. IA: t½ -- 25 s). When the experiment was done 
in the presence of I mM of amiloride, the efflux rate decreased 
significantly (Fig. 1A: t½>120 s). When NhaB proteolipo- 
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Fig. 1. NhaB mediated Na ÷ efflux and 22Na*:Na + exchange are inhibited by amiloride. (A) NhaB proteoliposomes (120,ug protein/ml) oaded with 
100 mM potassium acetate, 10 mM KPi, 0.1 mM NaP~ and 2ZNaC1 at pH 7 were prepared as described in section 2. The experiment was initiated 
by dilution of 4/~1 proteoliposomes into 500/11 of buffer with the same composition but devoid of Na ÷ with (A) or without (©) 1 mM amiloride. The 
reaction was stopped by addition of 2 ml of cold buffer and filtration through 0.2 pM filters which were counted by ?,-counter. The experiment was 
done in duplicates. (B) NhaB proteliposomes (120 pg protein/ml) oaded with 0.15 M ammonium chloride and 15 mM Tris, pH 7, were diluted 125 
fold into 0.15 M choline chloride, 15 mM Tris, pH 8.5, and 0.1 mM 22NaCI. Under these conditions aApH dependent Na ÷ uptake occured (m). 120 
seconds after the reaction was started, NaC1 was added to 10 mM to begin a 22Na:Na exchange reaction with (A) or without (©) the addition of 1 mM 
amiloride prior to the salt addition. 
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Fig. 2: Concentration-response profiles for inhibition of NhaB and 
NhaA mediated Na + uptake activity by amiloride. ApH driven Na + 
uptake experiments were done by dilution of proteoliposomes (4 #1 of 
120 #g protein/ml) oaded with 0.15 M ammonium chloride and 15 mM 
Tris, pH 7, 125-fold into 0.15 M choline chloride, 15 mM Tris, pH 8.5, 
carrier-free 22NaC1 and different concentrations of amiloride. Initial 
rate of uptake by NhaB proteoliposomes, was measured for 20 s with- 
out addition of unlabelled NaC1 (A) or with the addition of 1 mM NaCI 
to the reaction buffer (m). The initial rate of Na + uptake by NhaA 
proteliposomes was measured for 30 s without addition of unlabelled 
NaCI (o). 
somes were loaded with ammonium chloride and diluted to 
choline chloride with 22Na, Na + was taken up in a time- depend- 
ent manner and reached a steady state level after 2-3 min [7]. 
If unlabeled NaC1 was then added to 10 mM, a rapid 22Na+: Na ÷ 
exchange reaction was detected (Fig. 1B: t½ < 5 s). The rate of 
this reaction was markedly decreased by the addition of 1 mM 
amiloride prior to the NaC1 addition (Fig. 1B). These experi- 
ments strongly indicate that the NhaB protein is specifically 
inhibited by amiloride since the reactions described above are 
not driven by A]./H+ and therefore the inhibition cannot be 
attributed to uncoupling activity. 
The inhibition of ApH driven 22Na+ uptake by amiloride was 
then tested (Fig. 2). Under these conditions NhaB was inhibited 
by amiloride with a K0.5 of about 6 #M. When the reaction was 
performed in the presence of 1 mM NaC1 the inhibition profile 
shifted to the right with a K0.5 of 70 #M.  A Dixon plot of the 
data shown in Fig. 2 and additional data (not shown) with other 
NaC1 concentrations, indicated that amiloride is a competitive 
inhibitor of NhaB with an apparent Ki of 20 #M. Since amilo- 
ride does not inhibit NhaA [6] we could use NhaA prote- 
oliposomes as a control to confirm that the inhibition of NhaB 
under these conditions is specific and not due to an effect on 
the ApH. Indeed we were able to confirm our previous finding 
that amiloride does not influence NhaA activity significantly 
when measured under the same conditions as NhaB with con- 
centrations up to 1 mM (Fig. 2). 
Amiloride analogs, that bear branched carbon chains on the 
5-amino group, like ethyl isopropyl amiloride (EIPA) and 
methyl isobutyl amiloride (MIBA), are 100-1000-fold more 
potent inhibitors of the mammalian Na+/H + exchanger than 
amiloride itself [8,18]. We therefore checked the inhibition pat- 
tern of some derivatives on NhaB activity and the values for 
apparent half-maximal inhibition of ApH driven 22Na uptake 
are summarized in Table 1. In contrast to NHE-type an- 
tiporters, we found that 5-amino substitutions do not increase 
the inhibition potency of amiloride, and even slightly decrease 
it, regardless of the type of carbon group added at this position. 
All the derivatives of this type that we checked, namely, EIPA, 
MIBA, HMA (hexamethylene) and DMA (dimethyl) had K0.5 
in the range of 43-70 #M (Table 1). Further difference in the 
pharmacology of NHE antiporters and NhaB is seen with an- 
other derivative in which a benzene group is added to the 
guanidino moiety (benzamil): in the case of NhaB it has a 
similar inhibition potency to that of amiloride although it has 
much less potency in inhibition of the mammalian exchanger 
than amiloride (Table 1). 
The hallucinogenic drug, harmaline, was reported to inhibit 
mammalian Na+/H + exchanger [18,19]. The effect of harmaline 
on the Na ÷ efflux reaction from NhaB proteliposomes was 
tested. Addition of 1 mM harmaline into the dilution buffer 
slows the efflux rate 5-fold, practically to the same extent, as 
the addition of 1 mM amiloride (not shown). From an analysis 
of the concentration dependence of the inhibition of ApH 
driven Na + uptake by different concentrations of harmaline a 
K05 of 15 #M was found (Fig. 3). However, since harmaline is 
a hydrophobic weak base and therefore a potential protono- 
phore that could exert its inhibition by abolishing the ApH, we 
performed the same experiment with liposomes to which 
monensin was added. Monensin is a Na+/H + exchanging iono- 
phore and it catalyzes Na + uptake at the expense of the pH 
gradient generated by ammonium. Monensin driven Na ÷ up- 
take reaction is also inhibited by harmaline (Fig. 3) though at 
higher concentrations than the NhaB catalyzed reaction 
(K05 -- 75 ktM). These results confirm that harmaline is a potent 
inhibitor of NhaB (K05 = 15 pM), although it also shows quite 
a significant protonophoric activity. NhaA driven Na + uptake 
was inhibited at intermediate concentrations between the NhaB 
and monensin driven uptake (data not shown). Therefore from 
these results we cannot learn whether harmaline inhibits NhaA 
directly. 
Two other organic compounds that are known to inhibit 
mammalian Na+/H ÷ antiporters are clonidine and cimetidine 
[18,19]. When ApH driven 22Na+ uptake was tested in the pres- 
ence of clonidine, a concentration-dependent inhibition was 
observed although at concentrations higher than those ob- 
served for amiloride and harmaline with a K0.5 of 200 #M (data 
not shown). On the other hand cimetidine, a strong inhibitor 
Table 1 
Inhibition constants of Na+ uptake activity mediated by different Na+/ 
H ÷ antiporters for amiloride derivatives and other compounds a 
Inhibitor NhaB NHE-1 NHE-3 D. salina 
Amiloride 6.0 x 10 -6 1.6 × 10 -6 1.0 × 10 -4 
EIPA 5.3 x 10 -5 1.5 × 10 -8 2.4 × 10 -6 
HMA 4.3 x 10 -5 
MIBA 5.0 × 10 -5 
DMA 6.7 × 10 5 2.3 × 10 -8 1.4 × 10 8 
Benzamil 1.0 × 10 -5 1.2 × 10 -4 1.0 × 10 -4 
Harmaline 1.5 × 10 -5 1.4 x 10 -4 1.0 × 10 3 
Clonidine 2.0 × 10 -4 2.1 × I0  -4 6.2 × 10 -4 
Cimetidine > I × 10 -3 2.6 × 10 -5 6.2 × 10 -3 
1.5 x 10 -5 
8.0 x 10 -5 
8.2 × 10 -5 
3.0 × 10 6 
a The values hown are the half-maximal inhibition concentration (Kos) 
in M. Results for rat NHE-1 and NHE-3 are taken from Orlowsky [18] 
and for the Na+/H ÷ antiporter ofD. salina from Katz et al. [10]. NhaB, 
NHE-1 and NHE-3 were assayed with carrier-free 22NaCI and Na÷/H + 
antiporter of D. salina was assayed in the presence of 30 #M 22NaCI. 
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Fig. 3. Concentration-response profiles for inhibition of NhaB or 
monensin mediated Na + uptake activity by harmaline. Initial rates of 
ApH driven Na + uptake xperiments were conducted as described in 
Fig. 2 with different concentrations of harmaline in the reaction solu- 
tion. The experiment was done in duplicates with NhaB proteliposomes 
(A) or empty liposomes with addition of 2/IM monensin to the reaction 
mixture (e). Reaction was terminated after 20 s (NhaB mediated) or 
15 s (monensin mediated). 
of rat NHE-1 isoform [18], did not have any effect on NhaB 
activity at a concentration f 1 mM. 
Li + is a known substrate of both Na+/H ÷ antiporters of 
E. coli [4] and Mn 2+ is a substrate of mitochondrial Na+/H + 
exchanger [20]. Both LiC1 and MnCI2 inhibit NhaB dependent 
Na + uptake ([7] and data not shown). In order to assess the 
relative potency the effect of different cations concentrations 
on ApH driven Na ÷ uptake was tested. The K0. 5 values at a 
sodium concentration of 100/.tM were found to be 1.2 and 
5 mM for Mn 2+ and Li ÷, respectively. These data indicate 
that, surprisingly, NhaB has a higher affinity for Mn 2+ than to 
Li +, a situation similar to that observed for the mitochondrial 
Na+/H + exchanger [20]. 
4. Discussion 
In this report we used a purified and reconstituted system [7] 
to study the pharmacology of NhaB, a Na+/H ÷ antiporter f om 
E. coli. In the case of E. coli the use of a purified protein was 
particularly important since in the wild type cell, two specific 
antiporters, NhaA and NhaB, have been described. In addition, 
the use of a reconstituted system allows monitoring of activity 
at various modes: ApH-independent reactions namely 22Na+ ef- 
flux and 22Na :Na exchange and ApH-driven reactions, namely 
22Na uptake. NhaB activity is inhibited by amiloride in all the 
modes. Inhibition of ApH driven Na + uptake by amiloride was 
tested at varying concentrations and it was found that the 
inhibition is competitive with an apparent Ki of 20/.tM. This 
value is similar to the K~ found for Na+/H + antiporter activity 
in inverted membrane vesicles derived from a wild type E. coli 
strain (nhaA+nhaB +) [12]. Since NhaA is resistant to amiloride 
[6] the latter findings fit the notion that NhaB is the 'house 
keeping' antiporter and constitutes most of the Na+/H + an- 
tiporter activity of E. coli cells grown in low sodium medium 
and neutral pH [5,21]. another elevant conclusion from our 
studies is that amiloride has no significant uncoupling activity 
in the concentration range tested (up to 1 mM) since it has no 
effect on NhaA mediated, ApH driven Na + uptake. 
Table 1 summarizes the half-maximal inhibition concentra- 
tions for the different compounds tested for NhaB and for 
other Na+/H + antiporters. It can be seen that there is some 
resemblance in the inhibition pattern between NhaB and the 
Na+/H + antiporter of D. salina [10]. The K05 for inhibition by 
amiloride is 6 and 15 /.tM, respectively, for NhaB and the 
D. salina antiporter. These inhibition constants are relatively 
close to those found for the Rat NHE-1 and NHE-2 (1.6 and 
1.4 ¢tM, respectively) but much lower than the one found for 
NHE-3 (100,uM) [18,22]. The amiloride binding characteristics 
of NhaB are different from that of the mammalian exchanger 
isoforms ince amiloride derivatives with a branched alkyl res- 
idue at the 5-amino nitrogen are more potent han amiloride 
at least by two orders of magnitude in inhibiting mammalian 
NHE isoforms [8]. In this communication wefound that such 
derivatives (EIPA, MIBA, HMA and DMA) are less potent 
than amiloride in inhibiting NhaB by about 10 fold (Ko5 = 43- 
67/~M). The potency of EIPA and MIBA toward the D. salina 
antiporter isvery similar. The amiloride sensitive sodium chan- 
nel from epithelial cells has also a reduced affinity to these 
derivatives and the decline in inhibition potency due to these 
substitutions in the case of the channel is much more extreme 
than for NhaB [8]. The benzamyl derivative (addition of methyl 
benzene group to the guanidino moiety) is one of the most 
potent inhibitors of the epithelial Na ÷ channel but has reduced 
affinity to mammalian Na+/H + exchanger. We found that this 
derivative inhibits NhaB at concentrations slightly higher than 
amiloride (K05 = 10/.tM) And similar to the D. salina antiporter 
(3 ~M). 
Harmaline, a hallucinogenic drug that was also found to 
inhibit NHE isoforms [18,22], was found in this report o inhibit 
NhaB specifically with a K0.5 of 15/.tM. When the inhibition 
percentage was measured in a ApH driven Na + uptake assay, 
a K05 of 15/zM was obtained. However, we also found signifi- 
cant inhibition of monensin-mediated Na + uptake showing that 
this compound has considerable protonophore activity with a 
K,~.5 of 75/zM. Clonidine was found to inhibit NhaB activity 
with a K05 of 200/.tM and cimetidine did not have any effect 
on NhaB activity. 
Interestingly Mn 2+ has quite a high affinity to NhaB, compa- 
rable to that of Na + and significantly higher than that of Li ÷. 
The only Na+/H + antiporter reported to interact with Mn 2+ is 
the mitochondrial one [20]. 
It was reported before that amiloride inhibits growth of 
E. coli cells at alkaline pH [23,24]. It was suggested that this 
phenomenon results from the inhibition of Na+/H + activity 
which is responsible for pH regulation. This is probably not the 
case because of two reasons: (a) E. coli strain in which both 
nhaA and nhaB are deleted can grow at alkaline pH [2]; (b) 
growth of this strain is also inhibited by amiloride (not shown), 
indicating that this growth inhibition is not due to inhibition 
of specific Na+/H ÷ antiport activity. 
The growing interest in the diuretic amiloride is due to some 
possible implications for this drug other than its classical one. 
Amiloride inhalation as a treatment for cystic fibrosis (CF) 
patients, has been shown in independent s udies to increase 
mucous clearance and to retard the decline in lung function 
[25]. Amiloride was also suggested as an anti cancer drug since 
it was found to inhibit growth of colon cancer cells [26] and 
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angiogenesis [27], in vitro. Therefore the structure of amiloride 
binding sites is an important issue and was the subject of a few 
reports that used different approaches. In a study aimed to 
characterize the amiloride binding site of NHE-1, Pouyssegur 
and co-workers developed a procedure to isolate mutations 
which confer resistance to the amiloride analog MPA [28]. Two 
NHE-I mutants with decreased sensitivity to MPA were iso- 
lated and both had a replacement of Leu-167 to Phe. This Leu 
is found in a sequence which is conserved among NHE 
isoforms: ~64VFFLFLLPPI~73 which is located in the middle of 
the fourth putative trans-membrane segment. We found in the 
sequence of NhaB the pentamer 445FLFLL 45° which is identical 
to 5 amino acid of the putative amiloride binding site. However, 
it should be noted that in contrast o NHE-1, this sequence 
resides in the middle of the eleventh putative trans-membrane 
segment of NhaB and the homology between NhaB and NHE-1 
is not extended beyond that in this region. 
Of the two E. coli antiporters NhaB seems to be the most 
archaic one and is part of a novel family of proteins. It displays 
a weak but distinct homology to a membrane protein with 
unknown function in Mycobacterium leprae (Accession no. 
L10660; 24% identity, 55% similarity). In addition there is a 
limited homology to two transporters found in animal cells: the 
rat sodium-dependent sulfate transporter (24% identity, 50% 
similarity) [29] and the product of the mouse pink-eyed ilution 
gene (21% identity, 53% similarity) [30]. A conserved motif is 
observed in the four proteins: (S,T)X(L,I)GGXXTXX- 
GX(P,S)XNX(I,V). The significance of this motif is not known 
yet. 
The availability of these new potent inhibitors provides us 
with important tools to study ligand-protein i teractions and 
the relative levels of NhaB activity under various physiological 
conditions. 
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